2021 Year in Review - Ovarian Cancer

This review outlines treatment sequencing considerations for patients with recurrent ovarian cancer.
Results of the phase 2b VITAL trial suggest that immunotherapy with the autologous tumor cell vaccine gemogenovatucel-T as frontline maintenance in stage III/IV ovarian cancer is well-tolerated and shows clinical benefit in both BRCA-wild type and homologous recombinationā€“proficient subgroups.
Patient-reported outcomes of tolerability with adavosertib indicated greater incidence of fatigue, diarrhea, mucositis, and difficulty swallowing in patients receiving adavosertib and gemcitabine; however, no significant differences were noted in the symptomatic adverse-event profile for gastrointestinal events and anxiety.
Results of the phase 1b FORWARD II trial show that the MIRV/bevacizumab combination demonstrates promising antitumor activity with durable responses and favorable tolerability in high FRĪ± recurrent ovarian cancer.
Results of the NeoPembrOV phase 2 trial support the safe addition of pembrolizumab to neoadjuvant chemotherapy in patients deemed nonoptimally resectable. Although the addition of pembrolizumab resulted in an improved complete resection rate, it did not provide a progression-free survival benefit.
Primary results of a randomized phase 3 trial indicate that prolonged treatment with bevacizumab for up to 30 months does not provide survival benefit in patients with advanced ovarian cancer; therefore, bevacizumab treatment duration of 15 months remains the standard of care in this setting.
Results of a dose-escalation phase 1 study indicated that AVB-500 is well-tolerated in combination with paclitaxel or pegylated liposomal doxorubicin, with higher antitumor activity seen in combination with paclitaxel, and no previous exposure to bevacizumab.
Results of the multicohort phase 1b ACTION trial indicated that anlotinib plus TQB2450 shows encouraging antitumor activity and tolerable toxicity in patients with recurrent advanced ovarian cancer.
Pooled analysis data from the PRIMA, NOVA, and NORA trials suggest that patients with BRCA-mutated ovarian cancer derive a significant progression-free survival benefit from niraparib maintenance treatment, with no new safety signals.
Findings of a retrospective study indicate that patients with platinum-sensitive recurrent ovarian cancer were increasingly being administered maintenance therapy after second-line or third-line platinum-based chemotherapy regardless of biomarker status.
Page 1 of 3
Results 1 - 10 of 30

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Country